23S rRNA modulators(23S Ribosomal RNA modulators), 50S subunit modulators(50S ribosomal subunit modulators), EF-Tu inhibitors(bacterial elongation factor Tu inhibitors)

Therapeutic Areas

Infectious Diseases

Active Indication

Gram-Positive Bacterial InfectionsBacterial Infections

Inactive Indication

Staphylococcal Infections

Originator Organization

Hoechst Marion Roussel SA

Active Organization

Lepetit SA

Achillion Pharmaceuticals, Inc.

Inactive Organization

Hoechst Marion Roussel SA

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

100 Clinical Results associated with GE-37468A

100 Translational Medicine associated with GE-37468A

100 Patents (Medical) associated with GE-37468A

Literatures (Medical) associated with GE-37468A

01 Sep 1996·The Journal of antibiotics

Antibiotic GE37468A: a new inhibitor of bacterial protein synthesis. III. Strain and fermentation study.

Article

Author: Marinelli, Flavia ; Toppo, Giorgio ; Gastaldo, Luciano ; Quarta, Claudio

GE37468A is a new thiazolyl peptide antibiotic acting on Elongation Factor Tu, produced by fermentation of Streptomyces sp. ATCC 55365. The low (< 10 mg/liter) and poorly reproducible antibiotic productivity of the original soil isolate hampered the development of a scalable fermentation process. A tenfold increase of GE37468A productivity was achieved by selection of spontaneous morphochromatic variants, which appeared at high frequency in the wild type population. The higher producing ATCC 55365/O/5 colony was tyrosinase defective and blocked in the aerial mycelium differentiation (Amy-Mel- phenotype). The fermentation process of this stable and purified strain was rapidly optimized to achieve a further fourfold improvement in a fed-batch process.

01 Jan 1995·The Journal of AntibioticsQ4 · MEDICINE

Antibiotic GE37468 A: A Novel Inhibitor of Bacterial Protein Synthesis. II. Structure Elucidation.

Q4 · MEDICINE

Article

Author: Ferrari, P. ; Zerilli, L. F. ; Colombo, L. ; Stella, S. ; Selva, E.

GE37468 A is a novel antibiotic produced by Streptomyces sp. ATCC 55365. It has molecular mass 1309.48 and formula C59H52O12N14S5 and belongs to the thiazolyl peptide group of antibiotics. The structure was elucidated by 1H and 13C NMR and MS studies on intact molecule and its hydrolysis products. The antibiotic is a highly modified peptide containing a macrocycle and a side chain composed of a thiazole ring and two dehydroalanine units.

01 Jan 1995·The Journal of AntibioticsQ4 · MEDICINE

Antibiotic GE37468 A: A New Inhibitor of Bacterial Protein Synthesis. I. Isolation and Characterization.

Q4 · MEDICINE

Article

Author: Monnier, Francis Le ; Colombo, Luigi ; Selva, Enrico ; Montanini, Nicoletta ; Landini, Paolo ; Ferrari, Pietro ; Goldstein, Beth P. ; Denaro, Maurizio ; Stella, Sergio ; Ciciliato, Ismaela

GE37468 A is a new thiazolyl peptide antibiotic obtained by fermentation of Streptomyces sp. strain ATCC 55365. It inhibits bacterial protein synthesis by acting on elongation factor Tu and is structurally and functionally related to the GE2270 class of EF-Tu inhibitors. It is active in vitro against Gram-positive bacteria and Bacteroides fragilis, and protects mice against Staphylococcus aureus infection.

100 Deals associated with GE-37468A

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Gram-Positive Bacterial Infections	Preclinical	US	Achillion Pharmaceuticals, Inc.	03 Jun 2004
Bacterial Infections	Preclinical	AR	Lepetit SA	01 Jan 1995

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

GE-37468A

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation